跳至主要内容
临床试验/NCT07838831
NCT07838831已完成不适用

Ketamine Versus Dexmedetomidine as Adjuvants to Bupivacaine in Ultrasound Guided Bilateral Superficial Cervical Plexus Block in Patients Undergoing Thyroidectomy: a Prospective Randomized Controlled Study

Tanta University1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2025年8月31日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
60
试验地点
1
主要终点
Morphine consumption

研究概览

简要总结

The aim of this study is to compare the analgesic efficacy of Dexmedetomidine and Ketamine as adjuvants to Bupivacaine in ultrasound-guided Bilateral SCPB in patients undergoing thyroidectomy

详细描述

Thyroid gland disorders are relatively widespread. These conditions encompass a range of issues, including hypothyroidism, hyperthyroidism, goiter, thyroid nodules, thyroiditis, and various forms of thyroid cancer. While some thyroid conditions can be effectively managed through medical treatment alone, surgical intervention - particularly thyroidectomy - continues to play a central role in addressing both benign and malignant thyroid diseases.

Despite being a relatively safe operation, various complications can occur including postoperative pain, which remains a significant concern affecting patient comfort, recovery, and overall satisfaction.

Poorly controlled postoperative pain may result in adverse events that may prolong the patient's hospital stay, delay patient recovery, and affect the patient's experience with the health care system.

The aim of this study is to compare the analgesic efficacy of Dexmedetomidine and Ketamine as adjuvants to Bupivacaine in ultrasound-guided Bilateral SCPB in patients undergoing thyroidectomy Adequate postoperative pain management is essential for enhancing functional recovery, promoting early mobilization, and facilitating timely discharge from the hospital.

Post thyroidectomy pain may be treated with medical treatment like acetaminophen , non steroidal anti inflammatory drugs or opioids. However, many surgeons are reluctant to use NSAIDs so soon after the procedure because of gastric upset and bleeding disorders , also can be treated by local infiltration or regional block.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patients aged more than 18 years
  • •American Society of Anesthesiologists physical status I or II
  • •scheduled for elective thyroid surgery will be included in the study.

排除标准

  • •Patients who refuse to participate in the study.
  • •Patients presented with mental and memory dysfunction.
  • •Patients with history of allergy to local anesthetics.
  • •Patients with history of chronic use of pain killers )most days for more than 3 months).
  • •Patients presented with skin or soft tissue infection at the proposed site of needle.
  • •Pre-existing major organ dysfunction such as hepatic or renal impairment.

研究组 & 干预措施

Group C (Control group)

Placebo Comparator

Patients will only receive bilateral SCPB with 45mg bupivacaine diluted with normal saline (18 mL; 9 mL on each side) after intubation and before surgical incision.

干预措施: Group C (Control group) (Drug)

Group D (Dexmedetomidine group)

Experimental

Patients will receive general anesthesia plus US guided Bilateral SCPB with 45mg bupivacaine diluted with normal saline to 16mL and 1 μg/kg dexmedetomidine diluted with normal saline to 2mL (total volume, 18 mL; 9 mL on each side) after intubation and before surgical incision.

干预措施: Group D (Dexmedetomidine group) (Drug)

Group K (Ketamine group)

Experimental

Patients will receive general anesthesia plus US guided Bilateral SCPB with 45mg bupivacaine diluted with normal saline to 16 mL and 1 mg/kg ketamine diluted with normal saline to 2 mL (total volume, 18 mL; 9 mL on each side) after intubation and before surgical incision.

干预措施: Group K (Ketamine group) (Drug)

结局指标

主要结局

Morphine consumption

时间窗: 24 hours

total 24 hours Morphine consumption(mg)

次要结局

  • Assessment of post operative pain(immediately (T0),15 mins(T1),30 mins(T2),1 hour(T3),2 hours(T4),4 hours(T5)8 hours(T6),12 hours(T7),18 hours(T8),24 hours(T9) after arrival to recovery room)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ahmed Abdulhamid Sroor Abdulhamid Eissa

Resident

Tanta University

研究点 (1)

Loading locations...

相似试验